Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guangdong Hengrui Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HRS-9813-103 | P1 |
Not yet recruiting |
Unknown |
2025-06-01 |
|
HRS-9813-102 | P1 |
Not yet recruiting |
Progressive Pulmonary Fibrosis|Idiopathic Pulmonary Fibrosis |
2025-04-01 |
|
HRS-9813-101 | P1 |
Completed |
Healthy Volunteers |
2025-01-02 |